IP Library Granted Patent US 11,535,893
Granted Patent B2
US 11,535,893 · App. 16/446,255 · Granted Dec 27, 2022

Typing method

Inventors: Aroul Selvam Ramadass (Oxford, GB); Ewan Hunter (Oxford, GB); Alexandre Akoulitchev (Oxford, GB)
Assignee: Oxford BioDynamics PLC
C12Q1/6883C12Q1/6827C12Q2600/118
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,535,893
App. No.
16/446,255
Granted
Dec 27, 2022
Kind
B2
Abstract

The invention provides a method of determining the epigenetic chromosome interactions which are relevant to an epigenetic test for a neurodegenerative condition.

Claims (18)

1. A method of identifying a human individual in need of therapy for Alzheimer's disease and treating the identified human individual, the method comprising:

(A) assaying a blood sample from a human individual for ten chromosome interactions, wherein said assaying comprises the steps of:

(a) performing in vitro cross-linking of chromosome regions of the human individual which have come together in a chromosome interaction to form cross- linked nucleic acid;

(b) subjecting said cross-linked nucleic acid to restriction digestion cleavage with an enzyme to form cross-linked cleaved nucleic acids;

(c) ligating said cross-linked cleaved nucleic acid ends to form a ligated nucleic acid; and

(d) detecting the ligated nucleic acid to determine the presence or absence of a chromosome interaction and wherein the ten chromosome interactions are the following chromosomal interactions:

(i) the chromosome interaction on chromosome 12 that results in a ligated nucleic acid comprising SEQ ID NO: 8;

(ii) the chromosome interaction on chromosome 8 that results in a ligated nucleic acid comprising SEQ ID NO: 1;

(iii) the chromosome interaction on chromosome 8 that results in a ligated nucleic acid comprising SEQ ID NO: 19;

(iv) the chromosome interaction on chromosome 3 that results in a ligated nucleic acid comprising SEQ ID NO: 5;

(v) the chromosome interaction on chromosome 8 that results in a ligated nucleic acid comprising SEQ ID NO: 2;

(vi) the chromosome interaction on chromosome 10 that results in a ligated nucleic acid comprising SEQ ID NO: 24;

(vii) the chromosome interaction on chromosome 9 that results in a ligated nucleic acid comprising SEQ ID NO: 6;

(viii) the chromosome interaction on chromosome 11 that results in a ligated nucleic acid comprising SEQ ID NO:20;

(ix) the chromosome interaction on chromosome 3 that results in a ligated nucleic acid comprising SEQ ID NO:21; and

(x) the chromosome interaction on chromosome 7 that results in a ligated nucleic acid comprising SEQ ID NO:15;

(B) identifying the human individual as being in need of therapy for Alzheimer's disease when one or more of chromosome interactions (i)-(vii) are present and/or one or more of chromosome interactions (viii)-(x) are absent; and

(C) administering to the identified human individual an agent that is therapeutic for Alzheimer's disease.

Assignments (2)
CHANGE OF NAME Recorded Jun 29, 2022
From: OXFORD BIODYNAMICS LIMITED
To: OXFORD BIODYNAMICS PLC
Reel/Frame 060541/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2022
From: RAMADASS, AROUL SELVAM; HUNTER, EWAN; AKOULITCHEV, ALEXANDRE
To: OXFORD BIODYNAMICS LIMITED
Reel/Frame 060067/0853 →
Continuity (2)
Continuation PCTGB2016054076 · Dec 23, 2016
Related Publication 20190309367A1 · Oct 10, 2019